Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FANCG
REST API REST API
Homo sapiens
FANCG is differentially expressed in 165 experiments: 61 organism parts: endometrium, mammary gland, ... (59 more);, 60 disease states: normal, adrenocortical carcinoma, ... (58 more);, 53 cell types 255 cell lines 26 compound treatments and 43 other conditions.
Synonyms FAG, XRCC9
Orthologs A6QQ29_BOVIN (Bos taurus)   Fancg (Mus musculus)   fancg (Danio rerio)   FANCG (Gallus gallus)   Fancg (Rattus norvegicus)   fancg (Xenopus laevis)   FANCG (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, DNA repair, cytoplasm, damaged DNA binding, nucleus, spermatid development, binding, nucleoplasm, cell cycle checkpoint, response to DNA damage stimulus, response to radiation, mitochondrion organization, mitochondrion, Fanconi anaemia nuclear complex, ovarian follicle development
InterPro Term TPR_repeat
UniProt Accession O15287, Q53XM5, C9JSE3, B4DE21, F8WC08
Gene-Disease Assocation FANCONI ANEMIA, COMPLEMENTATION GROUP G; FANCG, FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA
Search EB-eye ENSG00000221829
Show more properties
Experimental Factors
Organism part

studied in E-MTAB-37, E-GEOD-6573, E-MEXP-1251, E-GEOD-18105, E-MTAB-69, ... (11 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22152, E-GEOD-14464, E-GEOD-19639, E-GEOD-24147, ... (23 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-6013, E-GEOD-3202
MCF-7
2
E-GEOD-19639, E-GEOD-20081
SW480
2
E-MEXP-1014, E-MTAB-37
MKN45
1
E-GEOD-15460
HPAFII
1
E-MTAB-37
D283Med
1
E-MTAB-37
249 more value(s).


Cell type

studied in E-GEOD-18811, E-TABM-40, E-GEOD-6053, E-GEOD-20033, E-MEXP-1403, ... (24 experiments)

Factor Value U/D Experiments
endothelial cell
1
E-GEOD-3998
immortalized cell culture
1
E-GEOD-14990
mononuclear cell
1
E-GEOD-6053
squamous cell carcinoma
1
E-GEOD-17347
not specified
1
E-GEOD-11755
resting natural killer cell
1
E-TABM-702
47 more value(s).


Disease state

studied in E-GEOD-15960, E-GEOD-5563, E-GEOD-22148, E-GEOD-16363, E-GEOD-14895, ... (27 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
benign prostatic hyperplasia
1
E-MEXP-1243
liposarcoma
1
E-MTAB-37
HPV positive
1
E-GEOD-3292
clinically isolated syndrome
1
E-GEOD-14895
B-cell neoplasm
1
E-MTAB-37
54 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-3720, E-GEOD-6462, E-MEXP-2590, E-GEOD-5339, ... (14 experiments)

Factor Value U/D Experiments
4-hydroxytamoxifen
1
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
Cxcl12
1
E-GEOD-7307
17beta-estradiol
1
E-GEOD-2292
NaOH
1
E-MEXP-2590
20 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-20499, E-GEOD-21589, ... (7 experiments)

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-763, E-GEOD-17476, E-GEOD-21750, E-TABM-601, E-MEXP-1838, ... (8 experiments)

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-TABM-127, E-GEOD-20504, ... (8 experiments)

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1290, E-GEOD-19519, E-TABM-271, ... (16 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-GEOD-17636, E-GEOD-4600, ... (6 experiments)

Population
studied in E-MTAB-197

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (7 experiments)

Processing time: 0.322 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM